Homoquinolinic acid (HQA) is a potent excitotoxin[1] which is a conformationally-restricted analogue of N-methyl-D-aspartate (NMDA) and a partial agonist of the main/glutamate site of the NMDA receptor, with some selectivity for NR2B subunit-containing receptors.[2][3][4] It is approximately equipotent to NMDA and about five times more potent than quinolinic acid as an agonist of the NMDA receptor.[5] HQA has also been found to label a novel, yet uncharacterized binding site, which can be distinguished from the NMDA receptor with the use of 2-carboxy-3-carboxymethylquinoline (CCMQ), a selective ligand of the uncharacterized site.[6]
Clinical data | |
---|---|
Other names | Homoquinolinate |
ATC code |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
PDB ligand |
|
CompTox Dashboard (EPA) |
|
ECHA InfoCard | 100.164.902 |
Chemical and physical data | |
Formula | C8H7NO4 |
Molar mass | 181.147 g·mol−1 |
3D model (JSmol) |
|
| |
|